Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection

Luise Hassler, Jan Wysocki, Ian Gelarden, Anastasia Tomatsidou, Haley Gula, Vlad Nicoleascu, Glenn Randall, Jack Henkin, Anjana Yeldandi, Daniel Batlle
doi: https://doi.org/10.1101/2021.03.12.435191
Luise Hassler
1From Division of Nephrology/Hypertension, Department of Medicine and the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Wysocki
1From Division of Nephrology/Hypertension, Department of Medicine and the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Gelarden
1From Division of Nephrology/Hypertension, Department of Medicine and the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia Tomatsidou
2Department of Microbiology, The University of Chicago, Chicago, Illinois
3Ricketts Regional Biocontainment Laboratory, University of Chicago, Lemont, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haley Gula
2Department of Microbiology, The University of Chicago, Chicago, Illinois
3Ricketts Regional Biocontainment Laboratory, University of Chicago, Lemont, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vlad Nicoleascu
2Department of Microbiology, The University of Chicago, Chicago, Illinois
3Ricketts Regional Biocontainment Laboratory, University of Chicago, Lemont, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn Randall
2Department of Microbiology, The University of Chicago, Chicago, Illinois
3Ricketts Regional Biocontainment Laboratory, University of Chicago, Lemont, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Henkin
4Center for Developmental Therapeutics, Northwestern University, Evanston, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anjana Yeldandi
1From Division of Nephrology/Hypertension, Department of Medicine and the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Batlle
1From Division of Nephrology/Hypertension, Department of Medicine and the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: d-batlle@northwestern.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) uses full-length angiotensin converting enzyme 2 (ACE2), which is membrane bound, as its initial cell contact receptor preceding viral entry. Here we report a human soluble ACE2 variant fused with a 5kD albumin binding domain (ABD) and bridged via a dimerization motif hinge-like 4-cysteine dodecapeptide, which we term ACE2 1-618-DDC-ABD. This protein is enzymatically active, has increased duration of action in vivo conferred by the ABD-tag, and displays 20-30-fold higher binding affinity to the SARS-CoV-2 receptor binding domain than its des-DDC monomeric form (ACE2 1-618-ABD) due to DDC-linked dimerization. ACE2 1-618-DDC-ABD was administered for 3 consecutive days to transgenic k18-hACE2 mice, a model that develops lethal SARS-CoV-2 infection, to evaluate the preclinical preventative/ therapeutic value for COVID-19. Mice treated with ACE2 1-618-DDC-ABD developed a mild to moderate disease for the first few days assessed by a clinical score and modest weight loss. The untreated control animals, by contrast, became severely ill and had to be sacrificed by day 6/7 and lung histology revealed extensive pulmonary alveolar hemorrhage and mononuclear infiltrates. At 6 days, mortality was totally prevented in the treated group, lung histopathology was improved and viral titers markedly reduced. This demonstrates for the first time in vivo the preventative/ therapeutic potential of a novel soluble ACE2 protein in a preclinical animal model.

Competing Interest Statement

D. Batlle and J. Wysocki are coinventors of patents entitled 'Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2', 'Active low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye' and 'Shorter soluble forms of Angiotensin Converting Enzyme 2 (ACE2) for treating and preventing coronavirus infection.' D. Batlle is founder of Angiotensin Therapeutics Inc. D. Batlle has received consulting fees from AstraZeneca, Relypsa, and Tricida, all unrelated to this work. During the conduct of these studies, D. Batlle received unrelated support from National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785, as well as from a grant from AstraZeneca; G. Randall reports consultancy agreements with Optikira. J. Wysocki reports scientific advisor capacity for Angiotensin Therapeutics Inc. All remaining authors have nothing to disclose.

Footnotes

  • Conflict of interest statement: D. Batlle and J. Wysocki are coinventors of patents entitled “Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2”, “Active low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye” and “Shorter soluble forms of Angiotensin Converting Enzyme 2 (ACE2) for treating and preventing coronavirus infection.” D. Batlle is founder of Angiotensin Therapeutics Inc. D. Batlle has received consulting fees from AstraZeneca, Relypsa, and Tricida, all unrelated to this work. During the conduct of these studies, D. Batlle received unrelated support from National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785, as well as from a grant from AstraZeneca; G. Randall reports consultancy agreements with Optikira. J. Wysocki reports scientific advisor capacity for Angiotensin Therapeutics Inc. All remaining authors have nothing to disclose.

  • The revision was only to add an author, Haley Gula, that mistakingly had not been included on the original submission.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 15, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection
Luise Hassler, Jan Wysocki, Ian Gelarden, Anastasia Tomatsidou, Haley Gula, Vlad Nicoleascu, Glenn Randall, Jack Henkin, Anjana Yeldandi, Daniel Batlle
bioRxiv 2021.03.12.435191; doi: https://doi.org/10.1101/2021.03.12.435191
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection
Luise Hassler, Jan Wysocki, Ian Gelarden, Anastasia Tomatsidou, Haley Gula, Vlad Nicoleascu, Glenn Randall, Jack Henkin, Anjana Yeldandi, Daniel Batlle
bioRxiv 2021.03.12.435191; doi: https://doi.org/10.1101/2021.03.12.435191

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pathology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3514)
  • Biochemistry (7367)
  • Bioengineering (5347)
  • Bioinformatics (20325)
  • Biophysics (10046)
  • Cancer Biology (7777)
  • Cell Biology (11353)
  • Clinical Trials (138)
  • Developmental Biology (6453)
  • Ecology (9980)
  • Epidemiology (2065)
  • Evolutionary Biology (13357)
  • Genetics (9373)
  • Genomics (12614)
  • Immunology (7725)
  • Microbiology (19104)
  • Molecular Biology (7465)
  • Neuroscience (41153)
  • Paleontology (301)
  • Pathology (1235)
  • Pharmacology and Toxicology (2142)
  • Physiology (3180)
  • Plant Biology (6880)
  • Scientific Communication and Education (1276)
  • Synthetic Biology (1900)
  • Systems Biology (5328)
  • Zoology (1091)